Pharmacological targets revealed by myocardial postconditioning

被引:33
作者
Burley, Dwaine S. [1 ]
Baxter, Gary F. [1 ]
机构
[1] Cardiff Univ, Welsh Sch Pharm, Cardiff, Wales
基金
英国惠康基金;
关键词
MITOCHONDRIAL PERMEABILITY TRANSITION; K-ATP CHANNELS; LIMITS INFARCT SIZE; ISCHEMIA-REPERFUSION INJURY; ATRIAL-NATRIURETIC-PEPTIDE; AGONIST AMP 579; RECEPTOR AGONIST; RABBIT HEARTS; ISCHEMIA/REPERFUSION INJURY; CYCLOSPORINE-A;
D O I
10.1016/j.coph.2008.11.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Postconditioning is an intervention in which controlled, brief, intermittent periods of ischaemia at the onset of reperfusion protect myocardium from the lethal consequences of reperfusion ('reperfusion injury'). Postconditioning has been demonstrated in humans with acute myocardial infarction and offers the possibility of further limiting infarct size in patients undergoing reperfusion therapy. We review current research that focuses on the molecular mechanisms of postconditioning. The molecular pathways are incompletely mapped but they probably converge on suppression of mitochondrial permeability transition pore opening during early reperfusion, an event that is thought to promote cell death at reperfusion. A number of upstream signalling pathways, activated by autacoid factors, converge on this crucial target and these offer a range of realistic possibilities for pharmacological induction of a postconditioned state.
引用
收藏
页码:177 / 188
页数:12
相关论文
共 132 条
[1]   Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury [J].
Abdallah, Y ;
Gkatzoflia, A ;
Pieper, H ;
Zoga, E ;
Walther, S ;
Kasseckert, S ;
Schäfer, M ;
Schlüter, KD ;
Piper, HM ;
Schäfer, C .
CARDIOVASCULAR RESEARCH, 2005, 66 (01) :123-131
[2]   Postconditioning inhibits mitochondrial permeability transition [J].
Argaud, L ;
Gateau-Roesch, O ;
Raisky, O ;
Loufouat, J ;
Robert, D ;
Ovize, M .
CIRCULATION, 2005, 111 (02) :194-197
[3]   A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs [J].
Auchampach, JA ;
Ge, ZD ;
Wan, TC ;
Moore, J ;
Gross, GJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 285 (02) :H607-H613
[4]   REDUCTION IN MYOCARDIAL INFARCT SIZE BY THE NEW POTASSIUM CHANNEL OPENER BIMAKALIM [J].
AUCHAMPACH, JA ;
GROSS, GJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (04) :554-561
[5]   Effects of acidic reperfusion on arrhythmias and Na+-K+-ATPase activity in regionally ischemic rat hearts [J].
Avkiran, M ;
Ibuki, C ;
Shimada, Y ;
Haddock, PS .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 270 (03) :H957-H964
[6]   Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death [J].
Baines, CP ;
Kaiser, RA ;
Purcell, NH ;
Blair, NS ;
Osinska, H ;
Hambleton, MA ;
Brunskill, EW ;
Sayen, MR ;
Gottlieb, RA ;
Dorn, GW ;
Robbins, J ;
Molkentin, JD .
NATURE, 2005, 434 (7033) :658-662
[7]   Natriuretic peptides and myocardial ischaemia [J].
Baxter, GF .
BASIC RESEARCH IN CARDIOLOGY, 2004, 99 (02) :90-93
[8]   Adenosine A1 agonist at reperfusion trial (AART):: Results of a three-center, blinded, randomized, controlled experimental infarct study [J].
Baxter, GF ;
Hale, SL ;
Miki, T ;
Kloner, RA ;
Cohen, MV ;
Downey, JM ;
Yellon, DM .
CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (06) :607-614
[9]   Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway [J].
Bell, RM ;
Yellon, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (03) :508-515
[10]   Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS [J].
Bell, RM ;
Yellon, DM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (02) :185-193